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Frontal fibrosing alopecia (FFA) is a form of
cicatricial alopecia that predominantly affects perime-
nopuasal and postmenopausal women.1-4 Although
the precise cause is unknown, it is currently classified
as a primary lymphocytic cicatricial alopecia that is
closely related to lichen planopilaris (LPP). FFA not
only causes scarring hair loss but also frequently
causes skin atrophy within the frontal hairline.5,6
Until recently, the treatment for FFA has
mirrored the treatment algorithms used for other
primary lymphocytic scarring alopecias. Topical
steroids, steroid injections, hydroxychloroquine,
doxycycline, tetracycline and mycophenolate mo-
fetil have been the main treatments. However, in
the last few years, an increasing number of reports
have suggested a beneficial role for the 5 alpha
reductase inhibitory medications, finasteride and
dutasteride.4,6-8
To date, the published studies of FFA treatment
outcomes have focused on hair follicles—whether
they are lost, stabilized, or promoted to regrow. The
other important feature of the condition—cutaneous
atrophy—has not received much attention. Here, I
report a patient with FFA who experienced not only
marked frontal hair regrowth with the 5a-reductase
inhibitor, finasteride, but also a marked reversal of
cutaneous atrophy.CASE REPORT
A 51-year-old woman presented with a 9-year
history of asymptomatic frontal hair loss (Fig 1, A and
C, before treatment). Hair loss started at age 42 in the
preauricular area and extended to the entire frontal
hairline. The patient was premenopausal at the time
of first hair loss and entered menopause at age 49.the University of Toronto Hair Clinic, Women’s College
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oronto.ca.Eyebrowswere reduced in density but still present. A
proportion of existing hair follicles in the receded
hairline displayed perifollicular erythema and peri-
follicular scale. Marked atrophy was noted along the
frontal hairline, and facial veins were visible (Fig 1, A
and C ). Biopsy findings confirmed the diagnosis of a
lymphocytic cicatricial scarring alopecia consistent
with the clinical diagnosis of frontal fibrosing alope-
cia. Results of bloodwork, including iron and thyroid
studies, were normal. Initial treatments, including
hydroxychloroquine (6 month trial); betamethasone
valerate, 0.1 % cream (3 weeks); and tacrolimus, 0.1
% ointment (2 months), were not helpful and did not
lead to any clinical change. The patient then started
finasteride, 2.5 mg daily, and within 3 months
experienced a reduction in redness and reversal of
skin atrophy followed by hair regrowth in the fronto-
temporal scalp. Further improvements were noted at
1-year follow-up (Fig 1, C and D).
In addition to author’s assessment and patient’s
assessment of hair regrowth after finasteride treat-
ment, clinical measurements also supported hair
regrowth in the frontal hairline. In the author’s
practice, changes to frontal hairline in patients with
frontal fibrosing alopecia are followed with use of
clinical photography, dermoscopy, and a series of
standardized measurements. For assessing the fron-
tal hairline, the author draws a line (often with a
crayon) from the lateral canthus to the root of the
helix (LC-RH line). For most individuals, this distance
is between 6 and 7 cm. Three additional hatch marksJAAD Case Reports 2015;1:353-5.
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Fig 1. Hair regrowth and reversal of atrophy in a patient with frontal fibrosing alopecia. A and
C, Before introduction of finasteride. B and D, 12 months posttreatment with finasteride,
2.5 mg. Note hair regrowth and reduction in atrophy.
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Donovan 355are then drawn perpendicular to this line at 2 cm,
4 cm, and 6 cm starting from the lateral canthus. Four
separate perpendicular measurements are then
taken from the LC-RH line to the patient’s hairline:
one at the lateral canthus and 3 at 2, 4, and 6 cm from
the lateral canthus. For the patient in this report,
these measurements (right side) were 7.6 cm, 7.0 cm,
5.5 cm, and 3 cm before treatment and 7.5 cm,
6.5 cm, 3.5 cm, and 1.5 cm after treatment with
finasteride.
DISCUSSION
Emerging evidence suggests that 5a-reductase
inhibitors may be among the most effective treat-
ments for FFA.4,6-8 Although these drugs are not
approved by the US Food and Drug Administration
for use in women and must not be used in women of
childbearing potential, they are increasingly used off
label for treatment of postmenopausal FFA. Recent
studies by Vano-Galvan et al4 support the notion that
partial hair regrowthmay be possible for a significant
proportion of FFA patients treated with 5a-reductase
inhibitors. Specifically, 52 of 111 FFA patients (47 %)
experienced hair regrowth after treatment with these
drugs.4 To date, hair regrowth does not appear to be
a feature of any other class of drugs besides the 5a-
reductase inhibitors.
It is well recognized that atrophy is a part of the
clinical presentation of FFA. Atrophy can also be a
side effect of topical steroids or steroid injections
used to treat FFA. In our patient, atrophy was present
before initiation of the short course of topical
midpotency steroids; thus, atrophy cannot be attrib-
uted to use of topical steroids. Moreover, reversal of
atrophy cannot be attributed to cessation of topical
steroid therapies. The timing of improvement of both
atrophy and hair regrowth strongly favor this as an
effect of finasteride therapy.
Descriptive studies and rating scales to document
atrophy have not been undertaken. Of the main
published FFA studies, only a brief mention is made
to the atrophy6,9 or presence of dilated veins in
women with FFA.5,10 It is increasingly clear that
disease activity scales often applied for the closely
related condition, LPP, such as the Lichen Planopilaris
Activity Index are inadequate for evaluating treatmentresponses in FFA.3 The Lichen Planopilaris Activity
Index does not account for hair regrowth and places
significant emphasis on disease symptoms and the
positive pull test, both of which are less frequently a
feature of FFA than LPP.6 New activity scales are
needed that take into account variables such as
patient symptoms, clinical signs (perifollciular scale
and erythema), symptoms, speed of hairline advance-
ment, hair regrowth, and possibly changes in skin
atrophy. It would be helpful in the future to assess
changes in skin atrophy before and after treatment
with histology or ultrasonography. The assessment of
skin atrophy by clinical examination is an important
limitation of this study.
This case further documents the marked changes
in hair regrowth that are possible with use of 5a-
reductase inhibitors and raises the possibility that
reversal of cutaneous atrophy may also be a bona
fide associated treatment outcome to monitor.
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